Extrapolated to cancer patients this could mean that GABARAPL1 blocking antibodies could inhibit angiogenesis or neovascularisation and thereby inhibit tumour growth and increase susceptibility to therapeutic interventions. This evidence concerns the gene GABARAPL1 and neoplasm.